Literature DB >> 21169259

Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study.

Katie M O'Brien1, Stephen R Cole, Chiu-Kit Tse, Charles M Perou, Lisa A Carey, William D Foulkes, Lynn G Dressler, Joseph Geradts, Robert C Millikan.   

Abstract

PURPOSE: Previous research identified differences in breast cancer-specific mortality across 4 intrinsic tumor subtypes: luminal A, luminal B, basal-like, and human epidermal growth factor receptor 2 positive/estrogen receptor negative (HER2(+)/ER(-)). EXPERIMENTAL
DESIGN: We used immunohistochemical markers to subtype 1,149 invasive breast cancer patients (518 African American, 631 white) in the Carolina Breast Cancer Study, a population-based study of women diagnosed with breast cancer. Vital status was determined through 2006 using the National Death Index, with median follow-up of 9 years.
RESULTS: Cancer subtypes luminal A, luminal B, basal-like, and HER2(+)/ER(-) were distributed as 64%, 11%, 11%, and 5% for whites, and 48%, 8%, 22%, and 7% for African Americans, respectively. Breast cancer mortality was higher for participants with HER2(+)/ER(-) and basal-like breast cancer compared with luminal A and B. African Americans had higher breast cancer-specific mortality than whites, but the effect of race was statistically significant only among women with luminal A breast cancer. However, when compared with the luminal A subtype within racial categories, mortality for participants with basal-like breast cancer was higher among whites (HR = 2.0, 95% CI: 1.2-3.4) than African Americans (HR = 1.5, 95% CI: 1.0-2.4), with the strongest effect seen in postmenopausal white women (HR = 3.9, 95% CI: 1.5-10.0).
CONCLUSIONS: Our results confirm the association of basal-like breast cancer with poor prognosis and suggest that basal-like breast cancer is not an inherently more aggressive disease in African American women compared with whites. Additional analyses are needed in populations with known treatment profiles to understand the role of tumor subtypes and race in breast cancer mortality, and in particular our finding that among women with luminal A breast cancer, African Americans have higher mortality than whites. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21169259      PMCID: PMC3029098          DOI: 10.1158/1078-0432.CCR-10-1533

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  42 in total

1.  Fallibility in estimating direct effects.

Authors:  Stephen R Cole; Miguel A Hernán
Journal:  Int J Epidemiol       Date:  2002-02       Impact factor: 7.196

2.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

Authors:  Lisa A Carey; Charles M Perou; Chad A Livasy; Lynn G Dressler; David Cowan; Kathleen Conway; Gamze Karaca; Melissa A Troester; Chiu Kit Tse; Sharon Edmiston; Sandra L Deming; Joseph Geradts; Maggie C U Cheang; Torsten O Nielsen; Patricia G Moorman; H Shelton Earp; Robert C Millikan
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

3.  Using the National Death Index to obtain underlying cause of death codes.

Authors:  N Sathiakumar; E Delzell; O Abdalla
Journal:  J Occup Environ Med       Date:  1998-09       Impact factor: 2.162

4.  Causal diagrams for epidemiologic research.

Authors:  S Greenland; J Pearl; J M Robins
Journal:  Epidemiology       Date:  1999-01       Impact factor: 4.822

5.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

Authors:  T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

6.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

7.  Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status.

Authors:  W Y Huang; B Newman; R C Millikan; M J Schell; B S Hulka; P G Moorman
Journal:  Am J Epidemiol       Date:  2000-04-01       Impact factor: 4.897

8.  Epidemiology of basal-like breast cancer.

Authors:  Robert C Millikan; Beth Newman; Chiu-Kit Tse; Patricia G Moorman; Kathleen Conway; Lynn G Dressler; Lisa V Smith; Miriam H Labbok; Joseph Geradts; Jeannette T Bensen; Susan Jackson; Sarah Nyante; Chad Livasy; Lisa Carey; H Shelton Earp; Charles M Perou
Journal:  Breast Cancer Res Treat       Date:  2007-06-20       Impact factor: 4.872

9.  The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology.

Authors:  B Newman; P G Moorman; R Millikan; B F Qaqish; J Geradts; T E Aldrich; E T Liu
Journal:  Breast Cancer Res Treat       Date:  1995-07       Impact factor: 4.872

10.  Test of the National Death Index and Equifax Nationwide Death Search.

Authors:  J W Rich-Edwards; K A Corsano; M J Stampfer
Journal:  Am J Epidemiol       Date:  1994-12-01       Impact factor: 4.897

View more
  175 in total

1.  How do I treat "triple-negative" disease.

Authors:  Christos Vaklavas; Andres Forero-Torres
Journal:  Curr Treat Options Oncol       Date:  2011-12

2.  Lectin chromatography/mass spectrometry discovery workflow identifies putative biomarkers of aggressive breast cancers.

Authors:  Penelope M Drake; Birgit Schilling; Richard K Niles; Akraporn Prakobphol; Bensheng Li; Kwanyoung Jung; Wonryeon Cho; Miles Braten; Halina D Inerowicz; Katherine Williams; Matthew Albertolle; Jason M Held; Demetris Iacovides; Dylan J Sorensen; Obi L Griffith; Eric Johansen; Anna M Zawadzka; Michael P Cusack; Simon Allen; Matthew Gormley; Steven C Hall; H Ewa Witkowska; Joe W Gray; Fred Regnier; Bradford W Gibson; Susan J Fisher
Journal:  J Proteome Res       Date:  2012-03-13       Impact factor: 4.466

3.  Breast cancer characteristics and outcomes among Hispanic Black and Hispanic White women.

Authors:  Matthew P Banegas; Christopher I Li
Journal:  Breast Cancer Res Treat       Date:  2012-07-08       Impact factor: 4.872

4.  Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study.

Authors:  E H Allott; C-K Tse; A F Olshan; L A Carey; P G Moorman; M A Troester
Journal:  Breast Cancer Res Treat       Date:  2014-08-24       Impact factor: 4.872

Review 5.  Racial/Ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review.

Authors:  Megan C Roberts; Stephanie B Wheeler; Katherine Reeder-Hayes
Journal:  Am J Public Health       Date:  2015-04-23       Impact factor: 9.308

6.  Racial/ethnic disparities in inflammatory breast cancer survival in the Michigan Cancer Surveillance Program.

Authors:  Abdi T Gudina; Glenn Copeland; Amr S Soliman; Kelly A Hirko
Journal:  Breast Cancer Res Treat       Date:  2018-11-07       Impact factor: 4.872

7.  Racial Differences in Adjuvant Endocrine Therapy Use and Discontinuation in Association with Mortality among Medicare Breast Cancer Patients by Receptor Status.

Authors:  Albert J Farias; Xianglin L Du
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-05-17       Impact factor: 4.254

8.  Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.

Authors:  Carol Sweeney; Philip S Bernard; Rachel E Factor; Marilyn L Kwan; Laurel A Habel; Charles P Quesenberry; Kaylynn Shakespear; Erin K Weltzien; Inge J Stijleman; Carole A Davis; Mark T W Ebbert; Adrienne Castillo; Lawrence H Kushi; Bette J Caan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-02-12       Impact factor: 4.254

9.  The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.

Authors:  Jennifer R Bean; Sarah R Hosford; Lynn K Symonds; Philip Owens; Lloye M Dillon; Wei Yang; Kevin Shee; Gary N Schwartz; Jonathan D Marotti; Kristen E Muller; Kari M Rosenkranz; Richard J Barth; Vivian S Chen; Veena R Agarwal; Todd W Miller
Journal:  Breast Cancer Res Treat       Date:  2014-12-10       Impact factor: 4.872

10.  Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening.

Authors:  Ryan A Denu
Journal:  JAMA Oncol       Date:  2018-06-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.